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MEETING REPORT
Bridging genomics technology and biology
Miguel R Branco1,2,3
Abstract
A report on the UK Genome Science Meeting, held at
the University of Nottingham, UK, 2–4 September
2013.
This year’s newly named UK Genome Science Meeting
was the fourth edition of what was previously known as
the UK Next Generation Sequencing Meeting. The re-
naming reflects technological developments that con-
tinue to redefine the meaning of next generation
sequencing, and the fact that high-throughput sequen-
cing is now a common tool in the scientific community.
Indeed, an enormous diversity of topics was presented at
this compact 3-day meeting, ranging from evolving tech-
nologies and bioinformatics, through to evolutionary
genomics, metagenomics and clinical applications,
amongst others. The meeting succeeded in portraying
how, in relatively few years, new sequencing technolo-
gies have revolutionized the way we do basic research in
just about every subject area, and are quickly making
their way through translational research, and into the
clinic and field.
Pushing the technological boundaries
At the base of current genomics research lie the power-
ful technologies that continuously aim to deliver more
data at lower cost. The ‘sequencing boom’ has driven the
creation of an assortment of new companies, as well as
heavy investment from existing companies, to provide
sequencing solutions, library preparation reagents and
bioinformatics support. This was evidenced by the 20 or
so companies represented at the meeting.
Scott Brouilette (Illumina) introduced a clever genome
phasing solution based on work from Stephen Quake’s lab
(Howard Hughes Medical Institute, Stanford University,
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USA) that relies on sequencing of large DNA fragments
(6 to 8 kb) aliquoted at limiting dilution. This allows
for segregation of haplotypes and resolution of cases of
compound heterozygosity, as well as improved assembly
of repetitive regions.
Clive Brown (Oxford Nanopore, UK) provided a
much-anticipated update that highlighted the technical
hurdles that Oxford Nanopore has had to overcome to
produce nanopore arrays that not only work but are also
shippable. Oxford Nanopore has now put more em-
phasis on the release of the portable MinION, for which
field-testing is ongoing, while it continues to develop the
modular GridION system. The technology can deliver
multi-kilobase reads, and can process 50 kb reads with
consistent data quality throughout. Much of the interest
in nanopores goes beyond their potential as DNA se-
quencers and, according to Brown, any given nanopore
type can distinguish about one-third of all known DNA
modifications, such that a combination of pores could
potentially resolve them all. The future may also see
RNA and protein sequencing through nanopores, but
for now we await the arrival of the first commercial
nanopore DNA sequencer.
One technology that can already deliver robust detec-
tion of DNA modifications, including 6-methyladenine
(6mA), is the PacBio system - Paul Coupland (Wellcome
Trust Sanger Institute, UK) shared his experience in
using it in a variety of contexts. The system has under-
gone significant upgrades at several levels and Coupland
reported sequencing, on average, 2 to 3 kb library inserts
(although the polymerase can deliver longer reads).
Apart from 6mA detection, some of the most interesting
applications of the technology that were touched on
were the sequencing of single-cell cDNA, where whole
transcripts are visible and isoforms resolved easily, and
the direct sequencing of viral and bacterial genomes
without the need for library preparation.
As genomics research moves into diagnostics, targeted
technologies that can deliver in-the-field results quickly and
cheaply are necessary. Jonathan O’Halloran (QuantuMDx
Group, UK) presented an impressive hand-held device
(Q-POC) that performs accurate multiple diagnostics in
© 2013 BioMed Central Ltd.
Branco Genome Biology 2013, 14:312
http://genomebiology.com/2013/14/10/312
less than 20 minutes from the point of sample collection
(and aiming to get under 10 minutes). The device incor-
porates a microfluidics chamber for rapid DNA amplifi-
cation and a nanowire-based hybridization system for
multiplexed detection of up to 100 pathogens or genetic
variants. The company is hoping the technology will
change medical diagnostics in developing countries where
the current need for expensive lab-based analyses is
hampering efficient treatment.
Managing variability
While generating sequencing data is now a routine
undertaking, extracting meaningful results often remains
a challenge. Bioinformatic analyses are not only vital for
dissecting out key results but can also feedback useful
information for experimental planning. Indeed, Geoff
Barton (University of Dundee, UK) and his team (talks
also by Marek Gierlinski and Nick Schurch, University
of Dundee, UK) performed careful analysis of RNA-seq
data to answer a basic question in differential expression
experiments: how many replicates are enough? In collab-
oration with Mark Blaxter (University of Edinburgh,
UK), the same RNA-seq experiment was performed 48
times and several commonly used algorithms for diffe-
rential expression analysis were tested to gauge how
variability affects the calling of differentially expressed
genes. While variability is bound to be different between
experimental set-ups, the study nonetheless establishes a
baseline of expected performance from replicate data
(for example, using edgeR and a twofold change cut-off
yielded an 80% true positive rate). Gierlinski pointed out
that badly correlated (or outlier) replicates are present
even in such a technically uniform experiment as this
one, and that inclusion of these outliers invalidates the
basic assumptions of differential expression algorithms.
It was estimated that with three replicates there is a 24%
chance of having one badly correlated replicate. One
way that technically poor replicates can be detected is by
using spike-in control RNAs, as was highlighted by
Schurch. These can also be used as powerful data
normalization controls, especially in cases where a sig-
nificant portion of genes is differentially expressed in
one preferred direction.
If variability in a standard RNA-seq experiment
already requires substantial attention, managing it in
single-cell transcriptomes is crucial. John Marioni
(EMBL-EBI, UK) and Xiuwei Zhang (EMBL-EBI and
Wellcome Trust Sanger Institute, UK) presented their
solutions to the problem, which again are based on the
inclusion of spike-in RNA controls. Marioni described
how such spike-in data can be used to model technical
variability, and therefore ensure that true inter-cellular
variability is being detected. Zhang demonstrated how the
carefully designed External RNA Control Consortium
(ERCC) sequences can impart information not only on
inter-cellular technical variability, but also on intra-
cellular technical variability, allowing one to get a firm
handle on the main problem of single-cell RNA-seq and
serving as a metric for the evaluation of potential protocol
developments.
From lab bench to clinic
Genomics research has amply demonstrated its invalu-
able use in translational research, mainly by identifying
variants associated with phenotypic traits and genes im-
plicated in rare diseases. Ultimately, genome sequencing
aims to provide personalized treatment solutions that
are most effective for a given individual. Zamin Iqbal
(Wellcome Trust Centre for Human Genetics, University
of Oxford, UK) showed how sequencing of regional
Plasmodium falciparum strains can help to design more
effective drug treatments. In a striking example, Iqbal
explained why a particular vaccine had failed in Africa -
whilst the allele targeted by the drug was present in the
reference strain, its frequency in African strains was only
16%. Prostate cancer treatment may also benefit from
sequencing approaches, as Ian Sudbery (University of
Oxford, UK) explained that patients that acquire resis-
tance to androgen deprivation treatment (ADT) com-
monly show upregulation of genes involved in Wnt
signaling. Using cell line models, Sudbery showed that
inhibition of Wnt signaling may be a useful strategy for
reversal of ADT resistance.
If these encouraging studies are representative exam-
ples of how genomics research may improve patient
care, then the ambitious plans outlined by Mark Caulfield
(Genomics England, UK) are going to constitute a
landmark transformation in our approach to clinical
diagnostics and treatment. Genomics England is a com-
pany that was recently set up by the Department of
Health to sequence 100,000 genomes of rare diseases,
common cancers and pathogens in NHS patients.
Among common cancers, expert panels have carefully
chosen to focus on childhood cancers and lung cancer;
similarly, HIV, hepatitis C and tuberculosis will be the
primarily targeted pathogens. Caulfield described the
plans of the company for patient sample collection, se-
quencing and data management, a well thought-through
process that has established solid ground from which
the project will develop. The first pilot study, planned
for 2014, will aim to sequence 2,000 genomes from pa-
tients with rare disease at 30× coverage. Beyond the pri-
mary objectives of encouraging new drug discovery and
providing faster diagnostics, Genomics England hopes to
drive down the cost of sequencing, and intends to train
the wider healthcare community to use the technology,
enabling the NHS to embrace genomic medicine at an
unparalleled scale. Caulfield is under no illusion that this
Branco Genome Biology 2013, 14:312 Page 2 of 3
http://genomebiology.com/2013/14/10/312
monumental effort may be seen as trying to walk before
you can crawl in the minds of many, but remains
confident that such leaps in human endeavor have proven
in the long term to be world-changing.
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